Premier Central Valley Provider Adopts Masimo SET®, Root®, Rad-97®, and Much More Across Multiple Hospitals
(BUSINESS WIRE) -- Masimo (NASDAQ: MASI) and Community Health System (CHS), based in Fresno, California, today announced that CHS is adopting a variety of advanced Masimo monitoring technologies and solutions across its campuses. CHS, a large four-hospital network, provides all levels of care across the Central Valley area of California, and is standardizing on Masimo SET® pulse oximetry and deploying 800 Root® Vital Signs Monitoring and Connectivity Hubs and 200 Rad-97® Pulse CO-Oximeters® with NomoLine® capnography, system-wide.
In the next phase of its medical technology expansion, CHS will focus on its patient surveillance monitoring initiative, with plans to implement Masimo Patient SafetyNet™ for centralized remote patient monitoring, taking advantage of Masimo Hospital Automation™ to seamlessly transfer patient data into electronic medical records (EMRs) to streamline nursing workflows and improve patient safety. An additional area of focus is expanding its perioperative monitoring capabilities, with planned installation of advanced Masimo rainbow® parameters such as SpHb® noninvasive and continuous hemoglobin monitoring and PVi® pleth variability index, alongside SedLine® brain function monitoring, O3® regional oximetry, and LiDCO® hemodynamic monitoring.
Joe Kiani, Founder and CEO of Masimo, said, “We are honored to work with partners like CHS to improve patient outcomes across the continuum of care. Their dedication to ensuring their clinicians have access to the tools they need to provide their patients with the highest possible quality care – the most advanced noninvasive monitoring technologies, the most versatile patient monitors, the most sophisticated automation and connectivity solutions – is inspiring.”
CHS Chief Nursing Officer and Senior Vice President Daniel Davis, R.N., said, “This expanded partnership allows us to integrate Masimo’s best-in-class, noninvasive monitoring technology across all the hospitals in our health system. We expect it to optimize workflows and provide additional insights into patient status that will ultimately help us improve patient outcomes.”
Cheri Provancha, DBA, DML, Vice President of Supply Chain, Security, and Clinical Engineering at CHS, added, “We are excited to expand our relationship with Masimo and provide our outstanding clinicians with the advanced noninvasive technologies, monitoring devices, and automation solutions they rely on to provide the best care possible for residents of the Central Valley.”
CHS is a private, not-for-profit healthcare network based in Fresno, California. The system operates four hospitals and a cancer institute along with several long-term care, outpatient, and other healthcare facilities. In 2014, CHS implemented Masimo SET® for Women and Children’s Services and Neonatal Intensive Care at the Community Regional Medical Center campus, and have since expanded to standardize across all care areas at their campuses.
Their positive experience using Masimo technology – for clinicians and patients alike – was the driving force behind this multi-wave expansion and standardization on Masimo technologies.
@Masimo | #Masimo
About Masimo
Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. In addition, Masimo Consumer Audio is home to eight legendary audio brands, including Bowers & Wilkins, Denon, Marantz, and Polk Audio. Our mission is to improve life, improve patient outcomes, and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.1 Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,2 improve CCHD screening in newborns3 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.4-7 Masimo SET® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world,8 and is the primary pulse oximetry at 9 of the top 10 hospitals as ranked in the 2022-23 U.S. News and World Report Best Hospitals Honor Roll.9 In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine® Brain Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography with NomoLine® sampling lines. Masimo’s family of continuous and spot-check monitoring Pulse CO-Oximeters® includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7®, Radius PPG®, and Radius VSM™, portable devices like Rad-67®, fingertip pulse oximeters like MightySat® Rx, and devices available for use both in the hospital and at home, such as Rad-97®. Masimo hospital and home automation and connectivity solutions are centered around the Masimo Hospital Automation™ platform, and include Iris® Gateway, iSirona™, Patient SafetyNet, Replica®, Halo ION®, UniView®, UniView :60™, and Masimo SafetyNet®. Its growing portfolio of health and wellness solutions includes Radius Tº® and the Masimo W1™ watch. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at www.masimo.com/evidence/featured-studies/feature/.
ORi and RPVi have not received FDA 510(k) clearance and are not available for sale in the United States. The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.
References
Published clinical studies on pulse oximetry and the benefits of Masimo SET® can be found on our website at http://www.masimo.com. Comparative studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles.
Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.
Taenzer A et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. Anesthesiology. 2010:112(2):282-287.
Taenzer A et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
McGrath S et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
McGrath S et al. Inpatient Respiratory Arrest Associated With Sedative and Analgesic Medications: Impact of Continuous Monitoring on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14 Mar. DOI: 10.1097/PTS.0000000000000696.
Estimate: Masimo data on file.
http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.
Forward-Looking Statements
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo monitoring technologies, monitors, and automation and connectivity solutions, as well as statements regarding CHS’ expansion of use of multiple Masimo technologies. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including Masimo monitoring technologies, monitors, and automation and connectivity solutions, contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; risks that CHS fails to realize the expected benefits of Masimo technologies or fails to implement Masimo technologies according to the plans described in this press release; risks related to COVID-19; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230612373372/en/
Permalink
https://www.aetoswire.com/en/news/1206202332785
Contacts
Masimo
Evan Lamb
949-396-3376
elamb@masimo.com